A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
Prostate Cancer
DRUG: Debio 4228
Maximum Plasma Concentration (Cmax) of Debio 4228, Cohorts 1 and 2: Predose and at multiple time points post-dose up to Day 169; Cohort 3: Predose and at multiple time points post-dose up to Day 169|Area Under the Concentration-time Curve of Debio 4228 Over 12 weeks (AUC84d), Cohorts 1 and 2: Predose and at multiple time points post-dose up to Day 84; Cohort 3: Predose and at multiple time points post-dose up to Day 169|Plasma Concentration of Debio 4228 at Week 12 (C84d), Cohorts 1 and 2: Post-dose on Day 84; Cohort 3: Post-dose on Days 84 and 168|Serum Concentration of Testosterone, Cohorts 1 and 2: Predose and at multiple time points post-dose from Days 1 to 85; Cohort 3: Predose and at multiple time points post-dose from Days 1 to 169
Number of Participants who Achieved and Maintained a Testosterone Castration (Testosterone Level of <50 [Nanograms per Deciliter] ng/dL and <20 ng/dL), Cohorts 1, 2, and 3: Days 29 to 85|Number of Participants who Maintained a Testosterone Castration (Testosterone Level of <50 ng/dL and <20 ng/dL), Cohort 3: Days 29 to 169|Time to Achieve Testosterone Castration (Testosterone Level of <50 ng/dL and <20 ng/dL), Cohorts 1 and 2: Day 1 up to Day 85; Cohort 3: Day 1 up to Day 169|Number of Participants who Experience Local Reactions Categorized as Erythema, Swelling, and Induration at the Injection Site, Cohorts 1 and 2: Immediately, at 2 and 24 hours post-injection on Day 1; Cohort 3: Immediately, at 2 and 24 hours post-injection on Days 1 and 85|Number of Participants who Experience Pain at Injection Site, Cohorts 1 and 2: Immediately, at 2 and 24 hours post-injection on Day 1; Cohort 3: Immediately, at 2 and 24 hours post-injection on Days 1 and 85|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) By Severity, Cohorts 1 and 2: Up to Day 169; Cohort 3: Up to Day 197|Number of Participants With Related TEAEs, Serious TEAEs, Adverse Events of Special Interest (AESIs), TEAEs Leading to Treatment Delay, and/or Discontinuation, and Death, Cohorts 1 and 2: Up to Day 169; Cohort 3: Up to Day 197|Number of Participants With Clinically Significant Abnormalities in Laboratory, Vital Signs, and Electrocardiogram (ECG) Parameters, Cohorts 1 and 2: Up to Day 169; Cohort 3: Up to Day 197|Percent Change From Baseline in Serum Prostate-Specific Antigen (PSA) Over Time, Cohorts 1 and 2: Baseline up to Day 85; Cohort 3: Baseline up to Day 169|Change From Baseline of Serum Luteinizing Hormone (LH) Over Time, Cohorts 1 and 2: Baseline up to Day 85; Cohort 3: Baseline up to Day 169|Change From Baseline in Serum Follicle-Stimulating Hormone (FSH) Over Time, Cohorts 1 and 2: Baseline up to Day 85; Cohort 3: Baseline up to Day 169
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.